Thermo Fisher Scientific (TMO) reported $10.36 billion in revenue for the quarter ended March 2025, representing a year-over-year increase of 0.2%. EPS of $5.15 for the same period compares to $5.11 a year ago.
The reported revenue represents a surprise of +1.11% over the Zacks Consensus Estimate of $10.25 billion. With the consensus EPS estimate being $5.10, the EPS surprise was +0.98%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Thermo Fisher performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenue Growth - Organic: 1% compared to the 0.2% average estimate based on five analysts.
- Revenues- Life Sciences Solutions: $2.34 billion versus $2.28 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +2.5% change.
- Revenues- Analytical Instruments: $1.72 billion versus $1.73 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +1.8% change.
- Revenues- Eliminations: -$482 million compared to the -$449.31 million average estimate based on four analysts. The reported number represents a change of +4.8% year over year.
- Revenues- Laboratory Products and Biopharma Services: $5.64 billion compared to the $5.61 billion average estimate based on four analysts. The reported number represents a change of -1.5% year over year.
- Revenues- Specialty Diagnostics: $1.15 billion compared to the $1.10 billion average estimate based on four analysts. The reported number represents a change of +3.5% year over year.
View all Key Company Metrics for Thermo Fisher here>>>
Shares of Thermo Fisher have returned -15.5% over the past month versus the Zacks S&P 500 composite's -6.6% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Thermo Fisher Scientific Inc. (TMO): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
